← VERONA PHARMA (VRNA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
VERONA PHARMA (VRNA)
Pharmaceutical Preparations · market cap $1.1B · as of 2026-07-20
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
15
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Verona Pharma (VRNA) is a pharmaceutical company focused primarily on respiratory diseases, with ensifentrine as its lead asset in Phase 3 development for COPD. The company generated $42M in revenue in 2024 after zero revenue in 2022–2023, suggesting early commercialization activity, though it remains deeply loss-making with a $173M net loss in 2024. At a ~$1.1B market cap, the stock is priced almost entirely on the commercial trajectory of ensifentrine.
The catalyst path
- 2026-12-15 (est.)Phase 2 · Ensifentrineimp 7/10
- 2027-03-01 (est.)Phase 2 · Ensifentrineimp 7/10
- 2027-09-24 (est.)Phase 2 · Nebulized Ensifentrine Suspension; 3 mgimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ensifentrine Dose 1 | Phase 2 | Coronavirus Infection |
| RPL554 suspension | Phase 2 | COPD |
| Nebulized Ensifentrine Suspension; 3 mg | Phase 2 | Non-cystic Fibrosis Bronchiectasis |
| Part A: RPL554 | Phase 2 | Pulmonary Disease, Chronic Obstructive |
| Glycopyrrolate (85 μg) | Phase 2 | Chronic Obstructive Pulmonary Disease |
| Tiotropium/olodaterol (Respimat) | Phase 2 | COPD |
| Ensifentrine 3 mg twice daily | Phase 3 | COPD |
| Ensifentrine | Phase 3 | Chronic Obstructive Pulmonary Disease |
| Ensifentrine 3 mg | Phase 2 | Chronic Obstructive Pulmonary Disease |
| RPL554 | Phase 2 | Cystic Fibrosis |
| Glycopyrrolate 21.25 mcg | Phase 2 | Chronic Obstructive Pulmonary Disease |
| 1.5 mg RPL554 plus tiotropium | Phase 2 | Chronic Obstructive Pulmonary Disease Moderate |
| Part B: RPL554 | Phase 2 | COPD |
| Formoterol | Phase 2 | Chronic Obstructive Pulmonary Disease |
| Salbutamol | Phase 2 | Chronic Obstructive Pulmonary Disease |
Price & technical context
3-month
+23.1%
6-month
+98.3%
12-month
+272.4%
52-wk range
$30.81–$106.91
vs 50-day MA
+0.9%
vs 200-day MA
+35.9%
Realized vol
48.3%
Max drawdown
-43.9%
Daily closes through 2025-10-06. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VRNA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.